Trial · NCT02049385
Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?
NCT02049385, Phase 1, Phase 2, Terminated, National Institute of Mental Health (NIMH); results first posted 2017-10-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression? Trials, record NCT02049385. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02049385
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?
- NCT number
- NCT02049385
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- National Institute of Mental Health (NIMH)
- Conditions
- Depression
- Interventions
- Diazoxide, Placebo
- First posted
- 2014-01-30
- Last updated
- 2017-10-13
- Results first posted
- 2017-10-13
- Limitations and caveats
As only 1 participant completed both treatment arms, no formal statistical analysis of the primary outcome (MADRS) possible. Study halted due to severe side effects \& lack of target (KATP channel) engagement measured by insulin sensitivity index.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MADRS Change at Day 7 | 7 days | Change in Montgomery Asberg Depression Rating Scale (MADRS) from baseline to 7 days post-treatment. The range of values is from 0 - 60, with a higher score indicating increased depressive symptoms. A score of 7-19 indicates mild depression; 20-34 indicates moderate depression; \>34 indicates severe depression. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | MADRS Change at Day 7 | 7 days | The analysis included those subjects who started treatment and completed treatment with Diazoxide or Placebo through at least 7 days. | percentage of change in units of scale | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| MADRS Change at Day 7 | Diazoxide | 0 | Full Range 0 to 100 | percentage of change in units of scale | |
| MADRS Change at Day 7 | Placebo | 10 | Full Range 0 to 100 | percentage of change in units of scale |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Intervention | STARTED | Diazoxide, Then Placebo | 4 | |
| First Intervention | STARTED | Placebo, Then Diazoxide | 2 | |
| First Intervention | COMPLETED | Diazoxide, Then Placebo | 1 | |
| First Intervention | COMPLETED | Placebo, Then Diazoxide | 2 | |
| First Intervention | NOT COMPLETED | Diazoxide, Then Placebo | 3 | |
| First Intervention | NOT COMPLETED | Placebo, Then Diazoxide | 0 | |
| Second Intervention | STARTED | Diazoxide, Then Placebo | 1 | |
| Second Intervention | STARTED | Placebo, Then Diazoxide | 2 | |
| Second Intervention | COMPLETED | Diazoxide, Then Placebo | 1 | |
| Second Intervention | COMPLETED | Placebo, Then Diazoxide | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events62
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Chest pain | Cardiac disorders | Diazoxide | 1 | 6 | |
| other | Chest pain | Cardiac disorders | Placebo | 0 | 3 | |
| other | Tachycardia | Cardiac disorders | Diazoxide | 1 | 6 | |
| other | Tachycardia | Cardiac disorders | Placebo | 1 | 3 | |
| other | Abdominal discomfort | Gastrointestinal disorders | Diazoxide | 1 | 6 | |
| other | Abdominal discomfort | Gastrointestinal disorders | Placebo | 1 | 3 | |
| other | Constipation | Gastrointestinal disorders | Diazoxide | 1 | 6 | |
| other | Constipation | Gastrointestinal disorders | Placebo | 0 | 3 | |
| other | Diarrhoea | Gastrointestinal disorders | Diazoxide | 1 | 6 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 0 | 3 |
1 to 10 of 62Source ClinicalTrials.gov
See all 62 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Diazoxide | 0 | 6 |
| Total, all-cause mortality | Placebo | 0 | 3 |
| Total, other adverse events | Diazoxide | 6 | 6 |
| Total, other adverse events | Placebo | 3 | 3 |
| Total, serious adverse events | Diazoxide | 0 | 6 |
| Total, serious adverse events | Placebo | 0 | 3 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Diazoxide vs Placebo: deaths from any cause | Trial comparisons |
| Diazoxide vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02049385
GET https://conductscience.org/api/trials/v1/NCT02049385/events?page=2